Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681131 · ClinicalTrials.gov registry record · Phase 2
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by BioAtla.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 20
- Study locations
NCT04681131 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by BioAtla. The registered enrollment target is 85 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04681131, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by BioAtla.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Conditions Studied
Interventions
- BIOLOGICAL PD-1 inhibitor
- BIOLOGICAL CAB-AXL-ADC
Study Locations (20)
California
- City of Hope - Duarte - Duarte
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center - Irvine
- California Research Institute - Los Angeles
- USC Norris - Los Angeles
- Cedars-Sinai - Los Angeles
- University of California, San Diego (UCSD) - Moores Cancer Center - San Diego
- American Institute of Research - Whittier
Florida
- Florida Cancer Specialists & Research Institute - Fleming Island
- Florida Cancer Specialists & Research Institute - Fort Myers
- Florida Cancer Specialist - St. Petersburg
- Moffitt Cancer Center - Tampa
- Florida Cancer Specialists - West Palm Beach
Kentucky
- Baptist Health Systems - Lexington
- University of Kentucky - Lexington
- Norton Cancer Institute, Brownsboro Hospital Campus - Louisville
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Georgia
- Augusta University - Georgia Cancer Center - Augusta
Louisiana
- Hematology/Oncology Clinic - Baton Rouge
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04681131
The ClinicalTrials.gov registry entry for NCT04681131 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is BioAtla, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which PD-1 inhibitor is the first listed.
NCT04681131 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04681131 about?
NCT04681131 is a clinical study titled "CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC". The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
What is the current status of trial NCT04681131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2021-03-17. Estimated completion is 2025-07-09.
What conditions does trial NCT04681131 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04681131?
The interventions under investigation include: PD-1 inhibitor (BIOLOGICAL), CAB-AXL-ADC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04681131?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04681131 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.